Anti-CD40 agonist antibodies: Preclinical and clinical experience

Update on Cancer Therapeutics

Volumn 2, Issue 2, 2007, Pages 61-65

  Khalil, Magi ^a   Vonderheide, Robert H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; CD40; Monoclonal antibody; Tumor immunology

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN EXPRESSION; APOPTOSIS; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXICITY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH;

EID: 34548580969     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2007.06.001     Document Type: Review

References (48)

1. Grewal I.S., and Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16 (1998) 111-135
2. Young L.S., Eliopoulos A.G., Gallagher N.J., and Dawson C.W. CD40 and epithelial cells: across the great divide. Immunol Today 19 11 (1998) 502-506
3. van Kooten C., and Banchereau J. CD40-CD40 ligand. J Leukoc Biol 67 1 (2000) 2-17
4. Quezada S.A., Jarvinen L.Z., Lind E.F., and Noelle R.J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 22 (2004) 307-328
5. Armitage R.J., Fanslow W.C., Strockbine L., Sato T.A., Clifford K.N., Macduff B.M., et al. Molecular and biological characterization of a murine ligand for CD40. Nature 357 (1992) 80-82
6. Allen R.C., Armitage R.J., Conley M.E., Rosenblatt H., Jenkins N.A., Copeland N.G., et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259 5097 (1993) 990-993
7. Ferrari S., Giliani S., Insalaco A., Al-Ghonaium A., Soresina A.R., Loubser M., et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci USA 98 22 (2001) 12614-12619
8. Etzioni A., and Ochs H.D. The hyper IgM syndrome-an evolving story. Pediatr Res 56 4 (2004) 519-525
9. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., and Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393 6684 (1998) 478-480
10. Ridge J.P., Di Rosa F., and Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393 6684 (1998) 474-478
11. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., and Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 6684 (1998) 480-483
12. French R.R., Chan H.T., Tutt A.L., and Glennie M.J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5 5 (1999) 548-553
13. Diehl L., den Boer A.T., Schoenberger S.P., van der Voort E.I., Schumacher T.N., Melief C.J., et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 5 7 (1999) 774-779
14. Sotomayor E.M., Borrello I., Tubb E., Rattis F.M., Bien H., Lu Z., et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 5 7 (1999) 780-787
15. Funakoshi S., Longo D.L., Beckwith M., Conley D.K., Tsarfaty G., Tsarfaty I., et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83 10 (1994) 2787-2794
16. Hess S., and Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J Exp Med 183 1 (1996) 159-167
17. Eliopoulos A.G., Dawson C.W., Mosialos G., Floettmann J.E., Rowe M., Armitage R.J., et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13 10 (1996) 2243-2254
18. von Leoprechting A., van der Bruggen P., Pahl H.L., Aruffo A., and Simon J.C. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 59 6 (1999) 1287-1294
19. Eliopoulos A.G., Davies C., Knox P.G., Gallagher N.J., Afford S.C., Adams D.H., et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 20 15 (2000) 5503-5515
20. Tong A.W., Papayoti M.H., Netto G., Armstrong D.T., Ordonez G., Lawson J.M., et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 7 3 (2001) 691-703
21. Wingett D.G., Vestal R.E., Forcier K., Hadjokas N., and Nielson C.P. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 50 1 (1998) 27-36
22. Hirano A., Longo D.L., Taub D.D., Ferris D.K., Young L.S., Eliopoulos A.G., et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93 9 (1999) 2999-3007
23. Ghamande S., Hylander B.L., Oflazoglu E., Lele S., Fanslow W., and Repasky E.A. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 61 20 (2001) 7556-7562
24. Vonderheide R.H. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 13 4 (2007) 1083-1088
25. Vonderheide R.H., Dutcher J.P., Anderson J.E., Eckhardt S.G., Stephans K.F., Razvillas B., et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 19 13 (2001) 3280-3287
26. Gladue R., Cole S., Donovan C., Paradis T., Alpert R., Natoli E., et al. In vivo efficacy of the CD40 agonist antibody CP-870,893 against a broad range of tumor types: impact of tumor CD40 expression, dendritic cells, and chemotherapy. J Clin Oncol 24 18S (2006) 103s
27. Bedian V., Donovan C., Garder J., Natoli E., Paradis T., Alpert R., et al. In vitro characterization and pre-clinical pharmacokinetics of CP-870,893, a human anti-CD40 agonist antibody. J Clin Oncol 24 18S (2006) 109s
28. Vonderheide R.H., Flaherty K.T., Khalil M., Stumacher M.S., Bajor D.L., Hutnick N.A., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25 7 (2007) 876-883
29. Coughlin C.M., Fleming M.D., Carroll R.G., Pawel B.R., Hogarty M.D., Shan X., et al. Immunosurveillance and survivin-specific T cell immunity in patients with high-risk neuroblastoma. J Clin Oncol 24 36 (2006) 5725-5734
30. Schultze J.L., Michalak S., Seamon M.J., Dranoff G., Jung K., Daley J., et al. CD40 activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100 (1997) 2757-2765
31. Tai Y.T., Catley L.P., Mitsiades C.S., Burger R., Podar K., Shringpaure R., et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 64 8 (2004) 2846-2852
32. Law C.L., Gordon K.A., Collier J., Klussman K., McEarchern J.A., Cerveny C.G., et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 65 18 (2005) 8331-8338
33. Kelley S.K., Gelzleichter T., Xie D., Lee W.P., Darbonne W.C., Qureshi F., et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 148 8 (2006) 1116-1123
34. Advani R.H., Forero-Torres A., Furman R.R., Rosenblatt J.D., Younes A., Shankles B., et al. SGN-40 (anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: evidence of anti-tumor activity from a phase 1 study. Blood 108 (2006) [Abstract 695]
35. Hussein M.A., Berenson J.R., Niesvizky R., Munshi N.C., Harrop K.L., McDonald M., et al. Results of a phase 1 trial of SGN-40 (anti-huCD40 mAb) in patients with relapsed multiple myeloma. Blood 108 (2006) [Abstract 3576]
36. Tong A.W., and Stone M.J. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 10 1 (2003) 1-13
37. Kapadia D., and Fong L. CTLA-4 blockade: autoimmunity as treatment. J Clin Oncol 23 35 (2005) 8926-8928
38. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 10 (2006) 1018-1028
39. Chiodoni C., Iezzi M., Guiducci C., Sangaletti S., Alessandrini I., Ratti C., et al. Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med 203 11 (2006) 2441-2450
40. Bergmann S., and Pandolfi P.P. Giving blood: a new role for CD40 in tumorigenesis. J Exp Med 203 11 (2006) 2409-2412
41. Nowak A.K., Robinson B.W., and Lake R.A. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63 15 (2003) 4490-4496
42. Ahonen C.L., Doxsee C.L., McGurran S.M., Riter T.R., Wade W.F., Barth R.J., et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 199 6 (2004) 775-784
43. Uno T., Takeda K., Kojima Y., Yoshizawa H., Akiba H., Mittler R.S., et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12 6 (2006) 693-698
44. Honeychurch J., Glennie M.J., Johnson P.W., and Illidge T.M. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 102 (2003) 1449-1457
45. Drake C.G., Jaffee E., and Pardoll D.M. Mechanisms of immune evasion by tumors. Adv Immunol 90 (2006) 51-81
46. Leach D.R., Krummel M.F., and Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 5256 (1996) 1734-1736
47. Yang Y.F., Zou J.P., Mu J., Wijesuriya R., Ono S., Walunas T., et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 57 18 (1997) 4036-4041
48. Ito D., Ogasawara K., Iwabuchi K., Inuyama Y., and Onoe K. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J Immunol 164 3 (2000) 1230-1235